1. A passive radio frequency identification (RFID) chip with a protection function against high-intensity electromagnetic fields comprising:
an antenna for receiving electromagnetic waves generated by an RFID reader and said antenna generating AC electrical signals to output to a power unit at an output of the antenna;
an inputoutput circuit;
a logic circuit;
the power unit for rectifying the AC electrical signals into DC (direct current) voltage and outputting the DC voltage to the logic circuit and the inputoutput circuit at an output of the power unit;
a variable-capacitance diode comprising an anode connected with the output of the antenna and a cathode connected to ground; and
a diode comprising an anode connected with the output of the power unit and a cathode connected with the output of the antenna.
2. The passive RFID chip according to claim 1, wherein the passive RFID chip has a safe voltage and the variable-capacitance diode has a threshold voltage greater than the safe voltage of the passive RFID chip.
3. The passive RFID chip according to claim 2, wherein the variable-capacitance diode is connected with the antenna in parallel and the connection accordingly decreases a quality factor of the antenna when the variable-capacitance diode switches on.
4. The passive RFID chip according to claim 3, wherein the variable-capacitance diode switches on when the output DC voltage of the power unit is higher than the threshold voltage of the variable-capacitance diode.
5. The passive RFID chip according to claim 1, wherein the variable-capacitance diode switches off when the output DC voltage of the power unit is lower than the threshold voltage of the variable-capacitance diode.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A method of determining whether a sample comprises biological material of a subject that has experienced an acute coronary syndrome selected from unstable angina and acute myocardial infarction, said method comprising:
combining an antibody that specifically binds to a polypeptide comprising the epitope sequence f-MII with the sample under conditions where the antibody can specifically bind to the epitope; and
detecting binding of the antibody to the polypeptide.
2. The method of claim 1, further comprising:
combining an antibody that specifically binds to a polypeptide comprising the epitope sequence f-MLF with the sample under conditions where the antibody can specifically bind to the epitope; and
detecting binding of the antibody to the polypeptide.
3. The method of claim 2, wherein the subject is a human subject.
4. The method of claim 1, wherein the subject is a human subject.
5. The method of claim 1, where in the sample is, blood or a protein-containing fraction thereof.
6. The method of claim 1, wherein the sample is cardiac tissue or comprises cell lysate thereof.
7. A method of determining whether a sample comprises biological material of a subject that has experienced an acute coronary syndrome selected from unstable angina and acute myocardial infarction, said method comprising:
combining an antibody that specifically binds to a polypeptide comprising the epitope sequence f-MLF with the sample under conditions where the antibody can specifically bind to the epitope; and
detecting binding of the antibody to the polypeptide.
8. The method of claim 7, further comprising:
combining an antibody that specifically binds to a polypeptide comprising the epitope sequence f-MII with the sample under conditions where the antibody can specifically bind to the epitope; and
detecting binding of the antibody to the polypeptide.
9. The method of claim 8, wherein the subject is a human subject.
10. The method of claim 7, wherein the subject is a human subject.
11. The method of claim 7, where in the sample is blood or a protein-containing fraction thereof.
12. The method of claim 7, wherein the sample is cardiac tissue or comprises cell lysate thereof.
13. A composition comprising:
an antibody that specifically binds to the epitope f-MLF; and
an aqueous sample comprising biological material of a human subject who has experienced an acute coronary syndrome selected from unstable angina and acute myocardial infarction, wherein the sample comprises a polypeptide that is released from cells of the subject as a result of unstable angina or acute myocardial infarction.
14. The composition of claim 13, wherein the antibody is bound to the polypeptide to form a complex.
15. The composition of claim 14, wherein the antibody-polypeptide complex is bound by detectable reagent.
16. A composition comprising:
an antibody that specifically binds to the epitope f-MII; and
an aqueous sample comprising biological material of a human subject who has experienced unstable angina or acute myocardial infarction, wherein the sample comprises a polypeptide that is released from cells of the subject as a result of the unstable angina or acute myocardial infarction.
17. The composition of claim 16, wherein the antibody is bound to the polypeptide to form a complex.
18. The composition of claim 17, wherein the antibody-polypeptide complex is bound by detectable reagent.
19. A device for detecting the presence of a polypeptide released from cells as a result of unstable angina or acute myocardial infarction, said device comprising a solid support to which is bound an antibody that specifically binds to the epitope f-MII.
20. The device of claim 19, wherein the solid support further comprises an antibody that specifically binds to the epitope f-MLF bound to the support.
21. The device of claim 19, wherein the solid support comprises plastic, nylon, nitrocellulose, or another substance suitable for use as a solid support in immunoassays.